Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype

• Published in: Metabolomics Vol. 17; no. 7; p. 58
• Main Authors: Mazzini, Flavia Noelia, Cook, Frank, Gounarides, John, Marciano, Sebastián, Haddad, Leila, Tamaroff, Ana Jesica, Casciato, Paola, Narvaez, Adrián, Mascardi, María Florencia, Anders, Margarita, Orozco, Federico, Quiróz, Nicolás, Risk, Marcelo, Gutt, Susana, Gadano, Adrián, Méndez García, Celia, Marro, Martin L., Penas-Steinhardt, Alberto, Trinks, Julieta
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2021; Springer Nature B.V
• Subjects: Biochemistry; Biomarkers; Biomedical and Life Sciences; Biomedicine; Body mass index; Cell Biology; Developmental Biology; Diagnosis; Fatty liver; Gene polymorphism; Genotype; Genotype & phenotype; Humans; Lecithin; Life Sciences; Lipase - genetics; Liver diseases; Membrane Proteins - genetics; Metabolic pathways; Metabolism; Metabolites; Metabolomics; Microbiota; Molecular Medicine; Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - genetics; Original Article; Phosphatidylcholine; Plasma; Plasma levels; Risk assessment; Single-nucleotide polymorphism; Steatosis; PNPLA3; Plasma; Metabolomics; Microbiota; Stool; Metabolic dysfunction-associated fatty liver disease
• ISSN: 1573-3882; 1573-3890
• DOI: 10.1007/s11306-021-01810-6

Introduction Non-invasive biomarkers are needed for metabolic dysfunction-associated fatty liver disease (MAFLD), especially for patients at risk of disease progression in high-prevalence areas. The microbiota and its metabolites represent a niche for MAFLD biomarker discovery. However, studies are not reproducible as the microbiota is variable. Objectives We aimed to identify microbiota-derived metabolomic biomarkers that may contribute to the higher MAFLD prevalence and different disease severity in Latin America, where data is scarce. Methods We compared the plasma and stool metabolomes, gene patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 single nucleotide polymorphism (SNP), diet, demographic and clinical data of 33 patients (12 simple steatosis and 21 steatohepatitis) and 19 healthy volunteers (HV). The potential predictive utility of the identified biomarkers for MAFLD diagnosis and progression was evaluated by logistic regression modelling and ROC curves. Results Twenty-four (22 in plasma and 2 in stool) out of 424 metabolites differed among groups. Plasma triglyceride (TG) levels were higher among MAFLD patients, whereas plasma phosphatidylcholine (PC) and lysoPC levels were lower among HV. The PNPLA3 risk genotype was related to higher plasma levels of eicosenoic acid or fatty acid 20:1 (FA(20:1)). Body mass index and plasma levels of PCaaC24:0, FA(20:1) and TG (16:1_34:1) showed the best AUROC for MAFLD diagnosis, whereas steatosis and steatohepatitis could be discriminated with plasma levels of PCaaC24:0 and PCaeC40:1. Conclusion This study identified for the first time MAFLD potential non-invasive biomarkers in a Latin American population. The association of PNPLA3 genotype with FA(20:1) suggests a novel metabolic pathway influencing MAFLD pathogenesis.